# Biogen Pharmach (NSE: BIOGEN) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/BIOGEN · Pivot · prices to 19 Oct 2026

With a market capitalisation of ₹34 Cr, it ranks 3313th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Financials sector; its industry is Capital Markets.

Its return on equity was −0.3% in FY25.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹34 Cr |
| ROE | −0.3% (FY25) |
| ROCE | −0.3% (FY25) |
| Debt to equity | 0 |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | — | — | ₹0 Cr | −83.6% | ₹0.00 |
| Q4 FY26 | — | — | −₹0 Cr | −130.5% | ₹0.00 |
| Q3 FY26 | — | — | ₹0 Cr | — | ₹0.01 |
| Q2 FY26 | — | — | −₹0 Cr | — | −₹0.01 |
| Q1 FY26 | — | — | ₹1 Cr | — | ₹0.01 |
| Q4 FY25 | — | — | ₹1 Cr | +59.5% | ₹0.02 |
| Q3 FY25 | — | — | −₹0 Cr | −616.7% | ₹0.00 |
| Q2 FY25 | — | — | −₹1 Cr | −238.9% | −₹0.02 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹0 Cr | −₹0 Cr |
| FY24 | ₹0 Cr | ₹2 Cr |
| FY23 | ₹0 Cr | ₹0 Cr |
| FY22 | ₹2 Cr | −₹0 Cr |
| FY21 | ₹2 Cr | −₹2 Cr |
| FY20 | ₹0 Cr | −₹0 Cr |

## Shareholding (30 Jun 2026)

- Domestic institutions: 0.00%
- Non-institutions: 100.00%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Sylph Ind](https://app.pivotnow.in/stock/SYLPH) | — | ₹35 Cr | — | — |
| [Supra Trends](https://app.pivotnow.in/stock/SUPRATRE) | — | ₹35 Cr | — | — |
| [Glance Fin](https://app.pivotnow.in/stock/GLANCE) | — | ₹34 Cr | — | — |
| [Sumedha Fiscal](https://app.pivotnow.in/stock/SUMEDHA) | ₹42.65 | ₹34 Cr | 14.1 | — |
| [Swasti Vinayaka](https://app.pivotnow.in/stock/SVARTCORP) | — | ₹34 Cr | — | — |
| [Yamini Invt](https://app.pivotnow.in/stock/YAMNINV) | — | ₹33 Cr | — | — |

## Questions and answers

### What is the market cap of Biogen Pharmach?

Biogen Pharmach's market capitalisation is ₹34 Cr (₹34 Cr) at the 19 Oct 2026 close, ranking 3313th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Biogen Pharmach?

Return on equity was −0.3% in FY25 and return on capital employed was −0.3% in FY25 (standalone figures).

### What is the shareholding pattern of Biogen Pharmach?

As of 30 Jun 2026: domestic institutions 0.00%, non-institutions 100.00%.

### Who are Biogen Pharmach's competitors?

The listed Financials companies closest to Biogen Pharmach by market cap are Sylph Ind, Supra Trends, Glance Fin, Sumedha Fiscal, Swasti Vinayaka and Yamini Invt.

### Is Biogen Pharmach a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Biogen Pharmach's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BIOGEN against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.